Lucentis And Avastin Stack Up In CATT, Forcing Genentech/Novartis To Play Defense

The efficacy of low-cost Avastin and pricier Lucentis for the treatment of wet-AMD are similar in the first head-to-head clinical trial to compare the two drugs, though Novartis and Genentech call out safety uncertainties.